0
0
55 words
0
Comments
Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously...
You are the first to view
https://newsroom.viatris.com/2023-10-01-Viatris-Announces-Agreements-on-Remaining-Planned-Divestitures-Upon-Closing-Would-Achieve-its-Original-Total-Target-of-a-Multiple-Above-12x-on-2022-Estimated-Adjusted-EBITDA
Create an account or login to join the discussion